Compare Adaptive Biotechnologies Corp (ADPT) vs Arko Corp. (ARKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Arko Corp. — how do they compare? Adaptive Biotechnologies Corp trades at $19.89 (market cap $3.33B), while Arko Corp. trades at $8.1 (market cap $880.66M). The key difference: Adaptive Biotechnologies Corp is far larger — about 3.8× Arko Corp.'s market cap, and Arko Corp. pays a 1.53% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ARKO | |
|---|---|---|
Market Cap | $3.33B | $880.66M |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $8.64 |
52-Week Low | $10.24 | $3.82 |
Enterprise Value | $3.19B | $3.05B |
Dividend Yield | — | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ARKO trades at $7.85, down 2.36% today, with a bullish technical signal from moving averages. The company reported Q1 2026 earnings of -$0.07 per share, beating expectations, but revenue has declined from $9.4B in 2023 to $7.6B in 2025. Net income margin remains thin at 0.38%, while the P/E ratio of 39.75 suggests high earnings expectations relative to current profits. Recent news highlights ARKO as a defensive pick amid inflation concerns.
The outlook is mixed: positive technical momentum and defensive stock characteristics offer upside, but weak revenue growth and low profitability pose risks. All covering analysts rate it Hold, indicating caution. Investment appeal hinges on margin improvement and stable cash flow to support dividends, though high debt and economic sensitivity remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →
